- Q2 2024 Acumen Pharmaceuticals Inc Earnings Call TranscriptAug 13, 2024$2.77 (+8.20%)Earnings
- Q1 2024 Acumen Pharmaceuticals Inc Earnings Call TranscriptMay 14, 2024$3.69 (+9.82%)Earnings
- Q4 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptMar 26, 2024$3.75 (-11.76%)Earnings
- Acumen Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptNov 13, 2023$2.03 (+6.84%)Earnings
- Acumen Pharmaceuticals Inc at UBS BioPharma Conference TranscriptNov 09, 2023
- Q2 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2023$7Earnings
- Acumen Pharmaceuticals, Inc. - Special Call TranscriptJul 17, 2023
- Acumen Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Q1 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2023$5.73 (+18.14%)Earnings
- Q4 2022 Acumen Pharmaceuticals Inc Earnings Call TranscriptMar 27, 2023$4.21 (+7.40%)Earnings
- Q2 2022 Acumen Pharmaceuticals Inc Earnings Call TranscriptAug 15, 2022$5.41 (+0.19%)Earnings
- Q1 2022 Acumen Pharmaceuticals Inc Earnings Call TranscriptMay 16, 2022Earnings
Acumen Pharmaceuticals, Inc. - Special Call Transcript
My name is Michelle, and I will be the operator for today's call. (Operator Instructions) Please note that this conference is being recorded. I'll now turn the call over to Alex Braun, Head of Investor Relations. Alex, you may begin.
Thank you, and welcome to the Acumen conference call to discuss the top line results from our first in-human Phase I INTERCEPT-AD trial, investigating ACU193, in early Alzheimer's disease. The majority of these data were presented yesterday, at the Alzheimer's Association International Conference, or AIC, in Amsterdam.
Please note that during today's call, we'll reference slides that are available on the webcast. If you've not already done so, please go to the Investors section of our website to access the webcast player. A PDF of the slides has been made available on our website as well. During this presentation, we'll be making forward-looking statements based on our current expectations relating to the clinical development of ACU193, and the potential
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)